Antibody targets the clinically validated pathway involving the epidermal growth factor receptor.
Life Science Pharmaceuticals signed a license agreement with Abbott to develop Antibody 806. The company will also have exclusive worldwide rights.
Antibody 806, which targets the clinically validated pathway involving the epidermal growth factor receptor (EGFr), may prove to be an important tool in the fight against cancer, according to the companies. The antibody is differentiated by its epitope targeting a transitional form of EGFr and has demonstrated the ability to target and bind to EGFr while showing essentially no targeting of normal tissues. Applications for 806 include multiple forms of cancer and certain noncancerous diseases.
The 806 antibody was generated by Lloyd Old, M.D., and his team at the New York Branch of the Ludwig Institute for Cancer Research (LICR). The antibody was then characterized in conjunction with the LICR’s Branches in New York, San Diego and Melbourne, Australia.
